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INTRODUCTION 
Chronic kidney disease (CKD) is a common health problem and about 5 to 
10% of the population of the world suffers from the disease [1]. The morbidity 
and mortality is contributed by co-morbid medical conditions such as 
cardiovascular disease, diabetes and lipid disorders and complications 
secondary to progression of kidney disease which include hypertension, 
anemia, secondary hyperparathyroidism and malnutrition. 
Although bone disease associated with secondary hyperparathyroidism is 
well established, vascular and valvular calcification and its relation to 
cardiovascular morbidity and mortality has gained importance in recent times. 
Though coronary artery calcification as assessed in terms of CAC score 
using CT based imaging is a strong predictor of cardiovascular events, more 
readily available and less expensive techniques such as 
• pulse wave velocity (PWV) 
• lateral lumbar radiography of aorta and 
• echocardiography 
have been demonstrated to have good correlation with vascular calcification 
that occurs in CKD [2]. 
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In this study, lateral abdominal X-ray is used to assess vascular calcification 
based on standardized scoring system which correlates with coronary artery 
calcification scores and hence predicts cardiovascular morbidity and mortality. 
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AIMS AND OBJECTIVES 
• To assess the vascular calcification status of 
CKD patients in different stages using lateral 
lumbar radiography 
• To study the biochemical parameters of 
mineral metabolism in different stages of 
CKD 
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REVIEW OF LITERATURE 
Chronic kidney disease is a global health threat with increasing incidence 
and prevalence. It is a major health problem in India with an estimated 
prevalence of 0.8%, which if projected to the 1 billion population of India will 
mean that currently 8 million people are suffering from the disease [3]. 
Chronic kidney disease is defined as either kidney damage or GFR <60 
mL/min/1.73 m2 for ≥3 months. Kidney damage is defined as pathologic 
abnormalities or markers of damage, including abnormalities in blood or urine 
tests or imaging studies [4]. 
CKD is classified into various stages based on the presence of kidney 
damage and decline in GFR [4]. 
Stage 1: Kidney damage with normal or elevated GFR of ≥90  
mL/min/1.73 m2 
Stage 2: Kidney damage with mild reduction in GFR in the range of 60-89 
mL/min/1.73 m2 
Stage 3: Moderate reduction in GFR in the range of 30-59 mL/min/1.73 m2 
Stage 4: Severe reduction in GFR in the range of 15-29 mL/min/1.73 m2 
Stage 5: Kidney failure with GFR below 15 mL/min/1.73 m2 or on dialysis 
 
Creatinine clearance calculated using Cockcroft-Gault equation is taken as 
estimated GFR (eGFR) [5]. Other formulas used to calculate eGFR include 
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MDRD formula and CKD-EPI formula both of which consider race as a 
parameter. Recently methods to calculate eGFR based on both serum creatinine 
and serum cystatin C have been developed which are claimed to be more 
accurate than the previous methods but are not widely used [6]. 
 =
140 −  × 	
ℎ
72 × 


× 0.85 
  
Note: 
• age in years 
• weight in kg 
• creatinine in mg/dL 
CAUSES OF CKD: 
Exact contribution from each cause varies depending on population 
characteristics. Common causes include the following: 
• Diabetes 
• Glomerulonephritis 
• Hypertension 
• Autosomal Dominant Polycystic Kidney Disease 
COMPLICATIONS OF CKD: 
CKD is a systemic disorder with manifestations involving almost every 
system of the body. Complications of CKD include the following: 
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• Electrolyte disturbances: hyperkalemia, hyponatremia 
• Acid-base disorders 
• Cardiovascular complications: hypertension, congestive cardiac 
failure, pericarditis 
• Hematologic complications: anemia, coagulopathy 
• Neurologic complications: uremic encephalopathy, peripheral 
neuropathy 
• Endocrine disorders: hypoglycemia as well as insulin resistance, 
sexual disturbances 
• Disorders of mineral metabolism 
MINERAL METABOLISM 
CALCIUM 
Normal adult human body contains 1-2 kg of calcium on average. Out of 
the total body store, ~99% is present in the bone. Approximately 250-500 mg of 
calcium moves in and out of bones due to the action of osteoblasts and 
osteoclasts. Apart from this, 0.5-1% of the calcium present in the skeleton is in 
equilibrium with extracellular fluid calcium [Figure 1]. 
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Figure 1: Calcium homeostasis 
The concentration of ionized calcium in the ECF is maintained within a 
narrow range because it plays critical role in neuromuscular activity, secretion 
and signal transduction. Intracellular cytosolic free calcium level is ~100 
nmol/L and is 10,000-fold lower than ionized calcium concentration in the 
blood and ECF. Cytosolic calcium serves a signaling function. In blood, total 
calcium concentration is normally 8.5–10.5 mg/dL, of which ~50% is ionized. 
The remainder is bound ionically to negatively charged proteins, 
predominantly albumin and immunoglobulins. Hence, alterations in serum 
protein concentrations directly affect the total blood calcium concentration 
even if the ionized calcium concentration remains normal. Albumin-corrected 
calcium [7,8] is calculated as follows: 
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Ionized calcium concentration in the ECF is controlled by regulatory 
mechanisms acting at intestine and kidneys mediated by PTH and 1,25(OH)2D. 
Ionized calcium has negative feedback control over PTH secretion by following 
mechanisms: 
• Activating calcium-sensing receptors (CaSRs) present in the 
parathyroid gland 
• Promoting the production of 1,25(OH)2D which in turn inhibits 
PTH production 
Intestinal calcium handling 
Ingested calcium is absorbed in two different ways: 
• Active (transcellular) transport: involves apical calcium entry via 
specific ion channels (TRPV5 and TRPV6), normally ranges from 20 
to 70% and occurs in  proximal small bowel 
• Passive (paracellular) transport: nonsaturable and approximates 5% 
of daily calcium intake 
Dietary intake of calcium regulates synthesis of 1,25(OH)2D which 
modulates active transport of calcium across the intestinal epithelium. Due to 
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this feedback control, net calcium absorption is maintained around ~200–400 
mg/d. About 100–200 mg/d of calcium is excreted as an obligate component of 
intestinal secretions and is not regulated by hormones. 
Renal calcium handling 
The daily load of absorbed calcium is excreted by the kidneys, which is 
tightly regulated by the concentration of ionized calcium in the blood. Out of 8-
10 g/d of calcium that is filtered by the kidneys, ~97-98% is reabsorbed. 
• Proximal tubule: 65% is reabsorbed through paracellular route 
coupled to sodium chloride reabsorption and is not under hormonal 
regulation 
• Cortical thick ascending limb of Henle's loop: 20% is reabsorbed 
through paracellular route and it requires paracellin-1 which is 
inhibited by elevated levels of calcium or magnesium acting via CaSR 
• Distal convoluted tubules: 10% is reabsorbed through transcellular 
pathway in which calcium enters the cell via apical calcium channels 
(TRPV5) across the gradient maintained by Ca2+-ATPases and 
Na+/Ca2+ exchangers present in the basolateral membrane under the 
control of PTH 
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Abnormal situations 
The homeostatic mechanisms that normally maintain a constant serum 
ionized calcium concentration may fail at extremes of calcium intake or when 
the hormonal systems or organs involved are compromised. 
• Low dietary calcium intake: increased PTH and 1,25(OH)2D levels 
mobilize calcium from bone and cause negative calcium balance 
• High dietary calcium intake: renal reabsorption is downregulated 
and leads to hypercalciuria and nephrocalcinosis 
• Deficiency or excess of PTH 
• Deficiency of excess of vitamin D 
• Intestinal disease 
• Renal failure 
PHOSPHORUS 
Total body phosphorus store is ∼600 g, of which 85% is present in the bone. 
Phosphorus differs from calcium in that the intracellular and extracellular 
concentrations do not have much difference. In cells and in the ECF, 
phosphorus exists predominantly as H2PO4− or NaHPO4− and the remaining as 
HPO42−. In serum, about 12% of phosphorus is bound to proteins and the 
normal range of elemental phosphorus in adults is 2.5–4.5 mg/dL. 
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Intestinal phosphorus handling 
Phosphate is widely available in foods. Net intestinal absorption of 
phosphorus is ~500–1000 mg/d and is absorbed efficiently by two ways: 
• Passive transport: up to 65% of ingested phosphorus can be 
absorbed 
• Active transport: involving Na+/PO42− co-transporters activated by 
1,25(OH)2D 
Phosphate absorption can be inhibited by phosphate binders like calcium 
salts, sevelamer acetate and lanthanum carbonate. Low serum phosphate 
stimulates renal proximal tubular synthesis of 1,25(OH)2D by suppressing 
blood levels of FGF23. 
Factors influencing serum phosphorus levels: 
• Circadian rhythm that produces a nadir between 7 and 10 a.m. 
• IV dextrose solutions in fasting subjects can decrease serum 
phosphate by 2 mg/dL due to rapid uptake into and utilization by 
cells 
Renal phosphorus handling 
Urinary excretion varies directly with dietary intake. Phosphorus is mainly 
reabsorbed in the proximal tubule through the apical membrane Na+/PO42− co-
transporters (NaPi-2 and NaPi-2c) which are down regulated by PTH [9,10]. 
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FGF23 can also impair phosphate reabsorption. The following factors affect 
renal phosphorus reabsorption: 
• Impair: Hypocalcemia, hypomagnesemia, and severe 
hypophosphatemia 
• Enhance: dehydration 
Hyperphosphatemia 
Serum phosphorus levels are controlled by altering the reabsorption by the 
NaPi-2 co-transporters in the proximal tubule for the given filtered load of 
phosphorus and GFR. The principal hormonal regulators of NaPi-2 activity are 
PTH and FGF23 [9,11]. 
In chronic kidney disease, reduction of GFR leads to retention of 
phosphorus. Hyperphosphatemia inhibits the synthesis of 1,25(OH)2D by the 
kidneys as well as stimulates the synthesis of PTH by the parathyroids both 
directly and indirectly (by lowering blood ionized calcium levels). Thus, 
hyperphosphatemia is a major cause of secondary hyperparathyroidism in renal 
failure and must be addressed in the early stages of the disease. 
Causes of hyperphosphatemia: 
I. Impaired renal phosphate excretion 
A. Renal insufficiency 
B. Hypoparathyroidism 
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1. Developmental 
2. Autoimmune 
3. After neck surgery or radiation 
4. Activating mutations of the calcium-sensing receptor 
C. Parathyroid suppression 
1. Parathyroid-independent hypercalcemia 
a. Vitamin D or vitamin Aintoxication 
b. Sarcoidosis, other granulomatous diseases 
c. Immobilization, osteolytic metastases 
d. Milk-alkali syndrome 
2. Severe hypermagnesemia or hypomagnesemia 
D. Pseudohypoparathyroidism 
E. Acromegaly 
F. Tumoral calcinosis 
G. Heparin therapy 
II. Massive extracellular fluid phosphate loads 
A. Rapid administration of exogenous phosphate (intravenous, oral, rectal) 
B. Extensive cellular injury or necrosis 
1. Crush injuries 
2. Rhabdomyolysis 
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3. Hyperthermia 
4. Fulminant hepatitis 
5. Cytotoxic therapy 
6. Severe hemolytic anemia 
C. Transcellular phosphate shifts 
1. Metabolic acidosis 
2. Respiratory acidosis 
The clinical consequences of hyperphosphatemia are due to the formation 
of widespread calcium phosphate precipitates and resulting hypocalcemia: 
• Tetany 
• Seizures 
• Accelerated nephrocalcinosis 
• Pulmonary or cardiac calcifications 
VITAMIN D 
Synthesis and Metabolism 
1,25-dihydroxyvitamin D [1,25(OH)2D] is a steroid hormone which is 
involved in the homeostatis of calcium and phosphorus. 
Sources of vitamin D include: 
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• Endogenous: vitamin D is produced from 7- dehydrocholesterol on 
exposure to ultraviolet radiation in the skin and this process is 
impaired by melanin and high solar protection sunscreens 
• Exogenous: vitamin D2 is the form present in plant sources whereas 
vitamin D3 is present in animal sources like fish oil, dairy products 
and egg yolk, both of which have equivalent biologic activity  
 
Figure 2: Synthesis of 1,25(OH)2D 
In the circulation vitamin D is present in association with vitamin D–
binding protein, an α-globulin synthesized in the liver. Vitamin D is 
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subsequently 25-hydroxylated in the liver. 25(OH)D is the major circulating 
and storage form of vitamin D. Further conversion to 1,25(OH)2D occurs in the 
proximal convoluted tubule cells of the kidney [Figure 2]. Factors regulating  
1- α hydroxylase are: 
• Inducers: PTH and hypophosphatemia 
• Inhibitors: calcium, FGF23 and 1,25(OH)2D 
Polar metabolites of 1,25(OH)2D are secreted into the bile and reabsorbed 
via the enterohepatic circulation. Impairment of this recirculation leads to 
accelerated losses of vitamin D metabolites. 
Actions of 1,25(OH)2D 
1,25(OH)2D mediates its biologic effects by binding to a member of the 
nuclear receptor superfamily, the vitamin D receptor (VDR), which has only 
one isoform, in contrast to the other members of its family. The VDR binds to 
target DNA sequences as a heterodimer with the retinoid X receptor, recruiting 
a series of co-activators that modify chromatin and approximate the VDR to 
the basal transcriptional apparatus, resulting in the induction of target gene 
expression. 
VDR has high affinity for 1,25(OH)2D compared to other vitamin D 
metabolites. Hence, in vitamin D toxicity, elevated levels of 25(OH)D can cause 
hypercalcemia by itself 
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• by directly interacting with the VDR 
• by displacing 1,25(OH)2D from vitamin D-binding protein 
 
Figure 3: Vitamin D metabolism 
Intestine: 
Vitamin D promotes intestinal calcium absorption by the following 
mechanisms: 
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• 1,25(OH)2D induces a calcium binding protein, calbindin 9K in the 
intestine which is involved in the active transport of calcium through 
the enterocyte 
• Vitamin D also induces the calcium transporters TRPV5 and TRPV6 
(transient receptor potential vanilloid) that are expressed in the 
apical membrane 
Bone: 
The VDR is expressed in osteoblasts. Genes regulated by VDR include the 
following bone matrix proteins: 
• Osteocalcin 
• Osteopontin 
Both 1,25(OH)2D and PTH induce the expression of RANK ligand, which 
promotes osteoclast differentiation and increases osteoclast activity, by binding 
to RANK on osteoclast progenitors and mature osteoclasts. This is the 
mechanism by which 1,25(OH)2D induces bone resorption. 
Parathyroid gland: 
Vitamin D has inhibitory effects on the parathyroid gland [Figure 3]: 
• Antiproliferative effects on parathyroid cells 
• Suppress the transcription of the parathyroid hormone gene 
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The effects of 1,25(OH)2D on the parathyroid gland are an important part 
of the rationale for current therapies directed at preventing and treating 
hyperparathyroidism associated with renal insufficiency. 
PARATHYROID HORMONE 
Physiology 
Calcium homeostasis is predominantly controlled directly as well as 
indirectly by PTH [Figure 4]. Hypocalcemia due to any cause is sensed by 
parathyroid and PTH synthesis is increased proportionately. The effector 
organs of PTH are bone and kidneys. PTH can mobilize calcium from bone and 
it can increase renal reabsorption of calcium. Apart from that PTH can also 
activate renal 1-α hydroxylase and promote the synthesis of 1,25(OH)2D. PTH 
increases intestinal absorption of calcium indirectly through vitamin D. 
 
Figure 4: Functions of PTH 
PTH 
↑ Reabsorption of 
calcium from kidneys 
↑ Mobilization of 
calcium from bone 
↑ Absorption of calcium 
from intestine 
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Transient rise and fall in serum calcium levels are controlled by PTH 
primarily by its effects on the bone and less on the renal clearance. Steady-state 
calcium levels are primarily affected by the actions of 1,25(OH)2D on intestinal 
absorption of calcium. 
Kidney: 
PTH acts at multiple sites in the kidneys: 
• Inhibits phosphorus transport (proximal tubule) 
• Augments calcium reabsorption (distal tubule) 
• Stimulates the renal 25(OH)D-1α-hydroxylase 
Bone: 
As much as 500 mg of calcium is transferred between the ECF and bone 
each day (a large amount in relation to the total ECF calcium pool), and PTH 
has a major effect on this transfer. The homeostatic role of the hormone can 
maintain calcium concentration in blood at the expense of bone 
demineralization. PTH has both direct and indirect actions on bone. Within 
minutes PTH can mobilize calcium from the bone. When chronically elevated, 
PTH increases the number of both osteoblasts and osteoclasts and increases the 
remodeling of bone; these effects manifest within hours after the hormone is 
given and persist for hours after PTH is withdrawn. 
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• Continuous exposure to elevated PTH: leads to increased bone 
resorption mediated by osteoclasts  
• Intermittent administration of PTH: elevated hormone levels for 1–2 
hours per day leads to a net stimulation of bone formation rather 
than bone breakdown 
Even though the primary action of PTH is activating the osteoclasts to 
promote bone demineralization, osteoclasts do not have PTH/PTHrP 
receptors. These receptors are present in the osteoblasts. Hence, activation of 
osteoclasts by PTH is indirect through osteoblasts. Cytokines are released by 
osteoblasts on stimulation by PTH and they in turn activate the osteoclasts. 
Presence of PTH/PTHrP receptor in the osteoblasts explains the bone-forming 
effects of PTH. 
Structure 
PTH is a peptide consisting of 84 amino acids. The 34 amino acids present 
in the amino-terminal portion are critical for the biologic actions of the 
hormone. Synthetic PTH fragments containing only the 11 amino-terminal 
amino acids are sufficient to activate the PTH/PTHrP receptor. The carboxyl-
terminal regions of the full-length PTH(1–84) molecule also can bind to a 
separate binding protein/receptor (cPTH-R), but this receptor has been 
incompletely characterized. Fragments shortened at the amino terminus 
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possibly by binding to cPTH-R can inhibit some of the biologic actions of full-
length PTH(1–84) and of PTH(1–34). 
Synthesis 
Parathyroid cells have multiple methods of adapting to increased needs for 
PTH production: 
• Secretion of preformed hormone in response to hypocalcemia 
(within minutes) 
• PTH mRNA expression is induced by sustained hypocalcemia 
(within hours) 
• Cellular replication to increase gland mass (within days) 
Parathyroid gland synthesizes preproparathyroid hormone containing 115 
amino acids which is further metabolized to release mature PTH. After a first 
cleavage step to remove the "pre" sequence of 25 amino acid residues, a second 
cleavage step removes the "pro" sequence of 6 amino acid residues before 
secretion of the mature peptide comprising 84 residues. 
Regulation of PTH Secretion 
Calcium present in the extracellular fluid interacts with a G protein-coupled 
receptor which is a calcium sensor and through that it controls the secretion of 
PTH. This receptor is a member of a distinctive subgroup of the GPCR 
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superfamily that is characterized by a large extracellular domain suitable for 
"clamping" the small-molecule ligand. 
• When the calcium level falls below the normal range (measured as 
total calcium), PTH secretion increases steeply; the ionized fraction 
of serum calcium being the one determining the hormone secretion 
• Severe intracellular magnesium deficiency impairs PTH secretion 
Metabolism 
The secreted form of PTH contains 84 amino acids. It is denoted as PTH(1–
84). Metabolism of PTH occurs in the liver and kidney and fragments 
containing less amino acid are produced. These fragments lack the critical 
amino-terminal sequence and hence they are biologically inactive. 
The rate of clearance of the secreted 84-amino-acid peptide from blood is 
more rapid than the rate of clearance of the biologically inactive fragments 
corresponding to the middle and carboxyl-terminal regions of PTH. 
Consequently, the interpretation of results obtained with earlier PTH 
radioimmunoassays is influenced by the nature of the peptide fragments 
detected by the antibodies. PTH assays fall into three categories [12]: 
• First generation assays: detect both PTH(1-84) as well as the 
fragments lacking amino-terminal sequence 
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• Second generation assays: did not detect fragments lacking amino-
terminal sequence but a truncated form of PTH denoted as PTH(7-
84) which is elevated primarily in patients with chronic renal 
insufficiency lead to misdiagnosis of secondary HPT and treatment 
causing adynamic bone disease 
• Third generation assays: detect only the full-length PTH(1-84) form 
but not readily available commercially at present 
Actions of PTH 
Both PTH and PTHrP bind to and activate the PTH/PTHrP receptor. The 
PTH/PTHrP receptor is G-protein coupled receptor and it is called as PTH1R. 
Although both ligands activate the PTH1R, the two peptides induce distinct 
responses in the receptor. 
PTH1R is characterized by the fact that it can bind to more than one G-
protein and activate different second messenger pathways. Hence, PTH can 
activate multiple pathways having different effects. PTH acts by activating 
protein kinases A and C and calcium channels with tissue specific responses: 
• Inhibition of phosphate and bicarbonate transport 
• Stimulation of calcium transport 
• Activation of renal 1α-hydroxylase 
• Increased bone turnover 
25 
 
CHRONIC KIDNEY DISEASE – MINERAL AND BONE DISORDER AND 
RENAL OSTEODYSTROPHY: 
Vitamin D deficiency that occurs in CKD leads on to hypocalcemia and 
secondary hyperparathyroidism. Pathologic changes that occur in bones are 
described as renal osteodystrophy. Abnormalities in mineral metabolism also 
manifest in soft tissues including blood vessels and heart valves. Hence, a new 
term ‘Mineral and Bone Disorder’ was coined to describe this spectrum of 
complications that occur in CKD. 
KDIGO defines CKD-MBD as a systemic disorder of mineral and bone 
metabolism due to CKD manifested by either one or a combination of the 
following: 
• Abnormalities of calcium, phosphorus, PTH or vitamin D 
metabolism 
• Abnormalities in bone turnover, mineralization, volume, linear 
growth or strength 
• Vascular or other soft-tissue calcification 
Renal osteodystrophy is an alteration of bone morphology in patients with 
CKD. It is one measure of the skeletal component of the systemic disorder of 
CKD-MBD that is quantifiable by histomorphometry of bone biopsy [1]. 
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Abnormalities of mineral metabolism 
In a cross sectional study, named ‘SEEK’ study, Levin et al studied around 
1,800 patients with CKD belonging to stages 3 to 5 who are not on dialysis [13]. 
They measured the levels of calcium, phosphorus, vitamin D and PTH in the 
serum. The levels of PTH started to rise early in the disease course starting from 
stage 3. The levels of calcium and phosphorus on the other hand were relatively 
stable until stage 5 [Figure 5]. 
 
Figure 5: Results of the SEEK study 
Vassalotti et al studied around 2,600 patients at increased risk of CKD from 
2005 to 2006 in KEEP, a program conducted by the National Kidney 
Foundation [14]. They also analyzed NHANES 1999 to 2004 data. This study 
also confirmed the results of the SEEK study that increased PTH level occurs 
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early in patients with stage 3, typically with normal calcium and phosphorus 
levels. 
Abnormalities in mineralization of bone 
Skeletal changes in MBD can take various forms and it also varies based on 
whether the patient is on dialysis or not [15]. Common abnormalities involving 
bones include the following: 
• Adynamic bone: a state of reduced bone turnover characterized by 
relatively low PTH, reduced osteoclasts and osteoblasts, reduced 
mineralization of bone but not associated with excess osteoid 
formation and it is common in patients on dialysis 
• Osteitis fibrosa: occurs secondary to hyperparathyroidism 
characterized by increased osteoclastic activity that leads on to 
increased bone resorption and formation of fibrosis and cysts 
• Osteomalacia: inadequate mineralization of the bone whereas osteoid 
formation is not affected and it is usually due to vitamin D deficiency 
• Mixed forms 
Prevalence of various types of skeletal changes [Figure 6] varies in CKD 
patients not on dialysis and patients on dialysis [1]. 
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Figure 6: Prevalence of various types of skeletal changes 
Whatever be the pathologic change in the bone, these skeletal changes 
reduce the tensile strength of the bone and make the bones more fragile and 
increase the risk of fracture. 
Vascular or other soft-tissue calcification 
CKD is associated with increased cardiovascular morbidity and mortality. 
Increased cardiovascular risk in CKD patients is due to the following factors: 
• Traditional risk factors like diabetes, hypertension and old age 
• Risk factors specific to CKD like albuminuria, anemia and electrolyte 
disturbances 
• Uremia by itself may promote atherosclerosis by various mechanisms 
including oxidative stress and inflammation. A hallmark of 
atherosclerosis in CKD is vascular calcification [16] 
Since cardiovascular risk in CKD patients is due to multiple factors apart 
from traditional risk factors, prediction of cardiovascular risk in this population 
requires measurement of non-traditional risk factors like vascular calcification. 
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MECHANISMS OF VASCULAR CALCIFICATION: 
Vascular calcification may occur either in tunica intima or tunica media of 
the vessel wall [Figure 7]. In atherosclerosis, calcification commonly occurs in 
intima. Medial calcification is common in CKD patients [17]. It may be 
independent of atherosclerosis and probably has a different pathogenesis from 
intimal calcification. Current evidence suggests that vascular calcification in 
CKD is a dynamically regulated process. 
 
Figure 7: Intimal calcification (A) and medial calcification (B) 
Vascular smooth muscle cells and osteoblasts arise from a mesenchymal 
precursor cell. A transcription factor, known as core-binding factor alpha 1 
(Cbfa1) possibly switches vascular smooth muscle cells to the osteoblast 
phenotype. The expression of bone related proteins like PTH, PTHrP, 
osteonection and BMP7 at the sites of medial arterial calcification also suggests 
the presence of osteoblastic activity in the vessel wall. Hyperphosphatemia has 
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been shown to induce osteoblastic changes in vascular smooth muscle cells and 
it is dependent on a sodium-dependent phosphate cotransporter, known as Pit-
1. Osteoprotegerin is a soluble marker belonging to tumor necrosis factor 
(TNF)-α receptor superfamily, the levels of which are elevated in ESRD 
patients. Osteoprotegerin has been demonstrated in vasculature and it inhibits 
osteoclastogenesis and leads to vascular calcification [Figure 8]. 
 
Figure 8: Imbalance between inhibitors and potentiators of vascular 
calcification in CKD 
Inhibitors of ectopic calcification include fetuin-A, matrix Gla protein and 
osteopontin. Fetuin-A is reduced in renal failure, especially in association with 
increasing inflammation in dialysis patients. Matrix Gla protein is found in 
normal arterial wall and inhibits mesenchymal cell differentiation into 
Inhibitors Potentiators
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osteogenic phenotype. Osteopontin is also a negative regulator of calcification 
[16,18]. 
CONSEQUENCES OF VASCULAR CALCIFICATION: 
Medial calcification leads to increased vascular stiffness and reduced 
vascular compliance. It results in increased pulse wave velocity, systolic blood 
pressure and fall in diastolic blood pressure. Pulse pressure is widened as a 
result [Figure 9]. Medial calcification also has an impact on plaque 
vulnerability. These factors result in adverse cardiovascular consequences [18]. 
 
Figure 9: Consequences of medial calcification 
  
Medial calcification 
↑ Vessel stiffness 
↑ Pulse wave velocity ↑ Pulse pressure 
↓ Coronary perfusion 
↑ Afterload 
Left ventricular hypertrophy 
Cardiac disease events 
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METHODS TO ASSESS VASCULAR CALCIFICATION: 
Electron Beam CT (EBCT) or Multi-Slice CT (MSCT) of coronary arteries 
The cardiovascular risk associated with CKD has a strong correlation with 
coronary artery calcification. It is measured by CT-based techniques such as 
EBCT and MSCT. Coronary artery calcium score is calculated based on the 
following characteristics: 
• Number of calcific lesions 
• Areas of calcific lesions 
• Peak Hounsfield computed tomographic numbers of the calcific 
lesions 
CAC score [2,19] is the most sensitive way of assessing vascular calcification 
in CKD. 
Pulse pressure 
Vascular calcification causes arterial stiffness that leads to increased systolic 
blood pressure and decreased diastolic blood pressure ultimately widening the 
pulse pressure. But studies comparing CAC score and pulse pressure have 
shown poor correlation between the two [20]. 
Pulse wave velocity 
Pulse wave velocity is a reproducible measure of arterial stiffness [19]. It is 
usually measured non-invasively using sonographic principles. Carotid and 
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femoral artery waveforms are recorded consecutively, analyzed with software 
and then pulse wave velocity is calculated. It has a strong correlation with 
cardiovascular events. 
Intima-media thickness (IMT) 
IMT is a measure of the thickness of tunica intima and tunica media of the 
vessel wall [21]. The measurement is usually done by external ultrasonography. 
IMT is used to detect the presence of atherosclerosis as well as to track the 
regression, arrest or progression of atherosclerosis. But the usefulness of 
measuring IMT over time is disputed. 
Multi-Slice CT of abdominal aorta 
Hanada et al utilized CT scan of the abdominal aorta to measure abdominal 
aortic calcification index (ACI) [22]. 10 slices of 10 mm thickness above the 
bifurcation of the aorta were analyzed. An area >1 mm2 having a density of 
≥130 Hounsfield units was taken as evidence for calcification. Each slice was 
divided into 12 segments radially and analyzed for the presence of calcification. 
ACI was calculated using the following formula: 
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Echocardiography 
Echocardiography is used to assess valvular calcification in both mitral and 
aortic valves [Figure 10]. Compared to mitral valve, aortic valve calcification 
has stronger association with CAC score. But overall valvular calcification does 
not correlate well. Since echocardiography is a non-invasive method and 
assessment of valvular calcification is relatively easy, the recent KDIGO 
guidelines recommend echocardiography in the routine evaluation of patients 
with CKD. 
 
Figure 10: Aortic valve calcification visualized on echocardiography 
Lateral lumbar radiography 
Calcification of abdominal aorta can be assessed using lateral lumbar 
radiography. Aorta lies lateral to the vertebral column in the upper abdomen 
and it becomes anterior before its bifurcation. So the calcification of the lower 
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portion of abdominal aorta can be visualized on a lateral film. Calcification 
usually starts in the lower portion of abdominal aorta and extends cranially in 
advanced cases. 
The utility of lateral lumbar radiography in the evaluation of abdominal 
aortic calcification was developed by Kauppila et al in 1997 [23]. Grading of the 
calcific lesions was performed and a scoring system was developed. 
Abdominal aorta will be visualized in front of the vertebral column as two 
vertical lines corresponding to the anterior and posterior walls of the aorta 
[Figure 11]. They are divided into four segments corresponding to L1 to L4 
vertebrae. Calcification is then assessed separately in each segment both in the 
anterior wall and posterior wall. Each portion is graded on a numerical scale 
from 0 to 3. Grade 0 indicates no calcification. Grade 1 indicates calcification 
extending less than 1/3 of the vessel wall vertically. Grade 2 corresponds to 
calcific lesions involving 1/3 to 2/3 of the wall. Grade 3 indicates more than 2/3 
of the vessel wall is calcified [Table 1]. 
The composite score for anterior–posterior severity is the sum of scores of 
individual aortic segments both for the anterior and posterior walls (maximum 
score 24). The affected segments score is the total number of aortic segments 
showing any level of calcification (maximum score 4) [Table 2]. 
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Figure 11: Lateral lumbar radiography of aorta 
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Table 1: Grading system 
Grading Description 
0 No calcific deposits in front of the vertebra 
1 
Small scattered calcific deposits filling less than 1/3 of 
the longitudinal wall of the aorta 
2 1/3 to 2/3 of the wall calcified 
3 2/3 or more of the wall calcified 
 
Table 2: Scoring system 
Level 
Affected 
segment 
Anterior 
wall range 
Posterior 
wall range 
Anterior-
posterior severity 
range 
L1 0 - 1 0 - 3 0 - 3 0 - 6 
L2 0 - 1 0 - 3 0 - 3 0 - 6 
L3 0 - 1 0 - 3 0 - 3 0 - 6 
L4 0 - 1 0 - 3 0 - 3 0 - 6 
Affected 
segments 
score 
0 - 4 Composite score 0 - 24 
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THERAPIES FOR MINERAL AND BONE DISORDER 
Management options currently available for CKD-MBD fall under three 
categories: 
1. Vitamin D analogs: Calcitriol, doxercalciferol, paricalcitol 
2. Calcimimetics: Cinacalcet HCl 
3. Phosphate binders: Calcium carbonate, calcium gluconate, 
sevelamer, lanthanum 
Vitamin D analogs 
Naturally occurring forms of vitamin D like cholecalciferol and 
ergocalciferol need renal activation which is deficient in patients with chronic 
renal insufficiency. Synthetic analogs which do not require in vivo activation 
are used in the treatment of secondary hyperparathyroidism [24]. 
Hypercalcemia and hyperphosphatemia are the common side effects of vitamin 
D therapy. 
Calcimimetics 
Cinacalcet acts on the CaSR in the parathyroid gland and inhibits the 
secretion of PTH [25,26]. Hypocalcemia remains a significant problem with 
calcimimetic therapy. Currently they are not recommended for the treatment of 
secondary hyperparathyroidism. 
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Phosphate binders 
Aluminium containing phosphate binders were used previously. 
Association of adynamic bone disease with aluminium toxicity lead to 
withdrawal of aluminium compounds in the CKD population. 
Calcium containing phosphate binders like calcium carbonate and calcium 
gluconate are now increasingly being used. But increased risk of vascular 
calcification associated with these agents precludes their use in patients at risk 
of calcification. Use of non-calcium containing phosphate binders is being 
investigated. 
Sevelamer is a non-calcium containing phosphate binder and it is 
recommended for patients who are at risk of vascular calcification [27,28,29]. 
Sevelamer has favorable effects on lipid profile and decreases the rate of 
progression of atherosclerosis [30]. 
Lanthanum carbonate is also a non-calcium containing phosphate binder, 
but it does not have additional benefits as sevelamer [31]. 
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MATERIALS AND METHODS 
Study Centre: 
Madras Medical College and Rajiv Gandhi Government General Hospital, 
Chennai 
Duration of the Study: 
6 months 
Study Design: 
Cross sectional study 
Sample Size: 
60 patients 
Study Population: 
Chronic kidney disease (as defined by K/DOQI [4]) patients attending the 
outpatient clinic of nephrology department at Rajiv Gandhi Government 
General Hospital, Chennai meeting the inclusion criteria were included in the 
study after screening for exclusion criteria. 
Inclusion Criteria: 
• CKD stage III-V patients 
• Aged ≥18 years 
• Duration since diagnosis ≥6 months 
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Exclusion Criteria: 
• Structural diseases of aorta 
• Patients on dialysis 
• CKD stage I and II 
Methodology: 
Patients have their history taken according to a questionnaire and subjected 
to clinical examination. 
Patients were subjected to the following investigations: 
• Blood urea 
• Serum creatinine 
• Hemoglobin 
• Serum albumin 
• Lipid profile 
• Serum calcium 
• Serum phosphorus 
• Serum PTH 
• USG KUB 
Lateral lumbar radiography of aorta was taken for all patients and 
abdominal aorta calcification was documented in terms of composite score and 
affected segment score. 
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Ethical Committee Clearance: 
Obtained 
Informed Consent: 
Obtained from all patients included in the study 
Statistical Analysis: 
Statistical analysis was done using SPSS software version 21.0 
Chi-square test, unpaired t-test and ANOVA were used in appropriate cases 
P value <0.05 was taken as statistically significant (95% confidence interval) 
Conflicts of Interest: 
None 
  
43 
 
OBSERVATIONS AND RESULTS 
STUDY POPULATION 
In our study, totally 60 patients were enrolled based on the inclusion and 
exclusion criteria. The study population consisted of patients who aged from 43 
years to 69 years. More than 50% of patients were between 61 and 65 years of 
age. Among 60 patients, 39 patients were males (65%) and 21 were females 
(35%) [Table 3, Figure 12, Figure 13, Figure 14]. 
Table 3: Age and sex distribution 
Age group 
[years] 
Sex 
Total P value 
Male Female 
≤50 
0 3 3 
0.11 
0% 14.3% 5% 
51-55 
5 1 6 
12.8% 4.8% 10% 
56-60 
9 4 13 
23.1% 19.0% 21.7% 
61-65 
20 12 32 
51.3% 57.1% 53.3% 
>65 
5 1 6 
12.8% 4.8% 10% 
Total 
39 21 60 
65% 35% 100% 
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Figure 12: Age and sex distribution 
 
 
Figure 13: Sex distribution 
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Figure 14: Age distribution 
METHOD OF ANALYSIS 
Patients were studied for their abdominal aortic calcification status in terms 
of composite score derived from lateral lumbar radiography. Analysis was 
performed in the following ways: 
1. Calcification is present (composite score >0) or absent (composite 
score = 0) 
2. Degree of calcification represented by the absolute value of 
composite score itself 
Parameters like sex, stage of CKD, serum calcium level and diabetic status 
were analyzed both for presence as well as degree of calcification. 
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AGE versus CALCIFICATION 
Calcification was noted in one third of the study population. Patients aged 
between 61 and 65 years represented the majority as 14 out of 20 patients (70%) 
who had calcification fell in that age group. None of the patients below 50 years 
of age had calcification (n = 3). No significant association was noted between 
age and presence of calcification (p = 0.293) [Table 4, Figure 15]. 
Table 4: Age versus calcification 
Age group 
[years] 
Calcification 
Total P value 
Present Absent 
≤50 
0 3 3 
0.293 
0% 7.5% 5.0% 
51-55 
2 4 6 
10.0% 10.0% 10.0% 
56-60 
2 11 13 
10.0% 27.5% 21.7% 
61-65 
14 18 32 
70.0% 45.0% 53.3% 
>65 
2 4 6 
10.0% 10.0% 10.0% 
Total 
20 40 60 
33.3% 66.7% 100.0% 
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Figure 15: Age versus calcification 
Age was not associated with the degree of calcification also (p = 0.062) 
[Table 5, Figure 16]. 
Table 5: Age versus degree of calcification 
Age group 
[years] 
n Mean 
Standard 
deviation 
P value 
≤50 0 0.00 0.000 
0.062 
51-55 2 1.50 0.707 
56-60 2 10.50 6.364 
61-65 14 8.00 3.464 
> 65 2 11.00 2.828 
Total 20 7.90 4.103 
 
0
2
4
6
8
10
12
14
16
18
20
≤50 51-55 56-60 61-65 >65
Age group [years]
Present
Absent
48 
 
 
Figure 16: Age versus degree of calcification 
SEX versus CALCIFICATION 
Out of 20 patients who showed evidence of calcification, 14 patients were 
males (n = 39) representing 70% and the remaining 6 patients were females (n 
= 21) accounting for 30%. Males outnumbered females in having calcification 
probably because they represent roughly two third of the study population. 
Statistical analysis did not reveal any association between sex and presence of 
calcification (p = 0.566) [Table 6, Figure 17]. Mean composite score among 
males was 7.64 (SD = 4.465) and among females was 8.50 (SD = 3.391). Degree 
of calcification also did not have any association with sex (p = 0.680) [Table 7, 
Figure 18]. 
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Table 6: Sex versus calcification 
Sex 
Calcification 
Total P value 
Present Absent 
Male 
14 25 39 
0.566 
70.0% 62.5% 65.0% 
Female 
6 15 21 
30.0% 37.5% 35.0% 
Total 
20 40 60 
33.3% 66.7% 100% 
 
 
 
Figure 17: Sex versus calcification 
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Table 7: Sex versus degree of calcification 
Sex n Mean 
Standard 
deviation 
P value 
Male 14 7.64 4.465 
0. 680 
Female 6 8.50 3.391 
 
 
Figure 18: Sex versus degree of calcification 
DURATION OF CKD versus CALCIFICATION 
None of the patients with duration of disease ≤2 years showed evidence of 
calcification. Twelve out of 23 patients (52.2%) with 4-6 years of disease and 3 
out of 4 patients (75%) with >6 years of disease had calcification. Duration of 
disease has got direct correlation with presence of calcification (p = 0.006) 
[Table 8, Figure 19]. 
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Table 8: Duration of CKD versus calcification 
Duration 
[years] 
Calcification 
Total P value 
Present Absent 
≤2 
0 6 6 
0.006 
0% 15.0% 10.0% 
2-4 
5 22 27 
25.0% 55.0% 45.0% 
4-6 
12 11 23 
60.0% 27.5% 38.3% 
>6 
3 1 4 
15.0% 2.5% 6.7% 
Total 
20 40 60 
33.3% 66.7% 100% 
 
 
Figure 19: Duration of CKD versus calcification 
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Mean composite score for patients with disease duration 2-4 years was 9.80 
(SD = 4.604); 7.92 for 4-6 years duration (SD = 3.370); and 4.67 for >6 years 
(SD = 5.508). Degree of calcification was not associated with duration of disease 
(p = 0.240) [Table 9, Figure 20]. 
Table 9: Duration of CKD versus degree of calcification 
Duration 
[years] 
n Mean 
Standard 
deviation 
P value 
≤2 0 0.00 0.000 
0.240 
2-4 5 9.80 4.604 
4-6 12 7.92 3.370 
>6 3 4.67 5.508 
Total 20 7.90 4.103 
 
 
Figure 20: Duration of CKD versus degree of calcification 
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SERUM CALCIUM LEVEL versus CALCIFICATION 
Mean serum calcium level was 9.12 mg/dL in stage 3 (n = 15), 8.74 mg/dL in 
stage 4 (n = 17) and 8.49 mg/dL in stage 5 (n = 28) CKD patients. Twelve out of 
20 patients (60%) with serum calcium level ≤8.5 mg/dL had evidence of 
calcification. On the contrary, only one patient out of 8 patients with serum 
calcium level >9.0 mg/dL showed evidence of calcification. Hypocalcemia was 
associated with an increased risk of vascular calcification (p = 0.018) [Table 10, 
Figure 21]. 
Table 10: Serum calcium level versus calcification 
Calcium 
[mg/dL] 
Calcification 
Total P value 
Present Absent 
≤8.5 
12 8 20 
0.018 
60.0% 20.0% 33.3% 
8.6-9.0 
7 25 32 
35.0% 62.5% 53.3% 
9.1-9.5 
1 5 6 
5.0% 12.5% 10.0% 
>9.5 
0 2 2 
0% 5.0% 3.3% 
Total 
20 40 60 
33.3% 66.7% 100% 
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Figure 21: Serum calcium level versus calcification 
Mean composite score was 9.58 (SD = 3.450) in patients with serum calcium 
level ≤8.5 mg/dL. The mean score showed a decreasing trend with higher 
calcium levels (p = 0.045). The mean score was 2.00 (SD = 0.000) in patients 
with calcium levels 9.1-9.5 mg/dL [Table 11, Figure 22]. 
Table 11: Serum calcium level versus degree of calcification 
Calcium 
[mg/dL] 
n Mean 
Standard 
deviation 
P value 
≤8.5 12 9.58 3.450 
0.045 
8.6-9.0 7 5.86 3.891 
9.1-9.5 1 2.00 0.000 
>9.5 0 0.00 0.000 
Total 20 7.90 4.103 
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Figure 22: Serum calcium level versus degree of calcification 
SERUM PHOSPHORUS LEVEL versus CALCIFICATION 
About 50% of patients with calcification had serum phosphorus levels in the 
range of 4.6-5.0 mg/dL. Patients with serum phosphorus levels in the range of 
4.1-4.5 mg/dL and 3.6-4.0 mg/dL contributed 15% (n = 3) and 20% (n = 4) 
respectively.  All patients with serum phosphorus levels >5.0 mg/dL showed 
evidence of calcification (n = 3). Two patients with serum phosphorus levels 
≤3.5 mg/dL did not have calcification. Higher serum phosphorus levels of 
phosphorus are associated with increased incidence of calcification (p = 0.002) 
[Table 12, Figure 23]. 
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Table 12: Serum phosphorus level versus calcification 
Phosphorus 
[mg/dL] 
Calcification 
Total P value 
Present Absent 
≤3.5 
0 2 2 
0.002 
0% 5.0% 3.3% 
3.6-4.0 
4 11 15 
20.0% 27.5% 25.0% 
4.1-4.5 
3 20 23 
15.0% 50.0% 38.3% 
4.6-5.0 
10 7 17 
50.0% 17.5% 28.3% 
>5.0 
3 0 3 
15.0% 0% 5.0% 
Total 
20 40 60 
33.3% 66.7% 100% 
 
Table 13: Serum phosphorus level versus degree of calcification 
Phosphorus 
[mg/dL] 
n Mean 
Standard 
deviation 
P value 
≤3.5 0 0.00 0.000 
<0.001 
3.6-4.0 4 2.75 1.708 
4.1-4.5 3 4.33 .577 
4.6-5.0 10 9.80 2.936 
>5.0 3 12.00 1.000 
Total 20 7.90 4.103 
 
57 
 
 
Figure 23: Serum phosphorus level versus calcification 
Serum phosphorus levels showed statistically significant correlation with 
degree of calcification (p <0.001) [Table 13, Figure 24]. 
 
Figure 24: Serum phosphorus level versus degree of calcification 
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SERUM PTH LEVEL versus CALCIFICATION 
Patients with PTH levels ≤50 pg/mL did not have calcification. Beyond that 
level presence of aortic calcification was noted in all the ranges of serum PTH 
level (p = 0.098) [Table 14, Figure 25].  
Table 14: Serum PTH level versus calcification 
PTH 
[pg/mL] 
Calcification 
Total P value 
Present Absent 
≤50 
0 3 3 
0.098 
0% 7.5% 5.0% 
51-100 
5 15 20 
25.0% 37.5% 33.3% 
101-150 
2 5 7 
10.0% 12.5% 11.7% 
151-200 
4 10 14 
20.0% 25.0% 23.3% 
201-250 
4 6 10 
20.0% 15.0% 16.7% 
>250 
5 1 6 
25.0% 2.5% 10.0% 
Total 
20 40 60 
33.3% 66.7% 100% 
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Figure 25: Serum PTH level versus calcification 
Serum PTH levels did not show any correlation with degree of calcification 
(p = 0.061) [Table 15, Figure 26]. 
Table 15: Serum PTH level versus degree of calcification 
PTH 
[pg/mL] 
n Mean 
Standard 
deviation 
P value 
≤50 0 0.00 0.000 
0.061 
51-100 5 6.40 5.367 
101-150 2 7.00 4.243 
151-200 4 4.50 1.291 
201-250 4 8.75 2.363 
>250 5 11.80 2.588 
Total 20 7.90 4.103 
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Figure 26: Serum PTH level versus degree of calcification 
SERUM CREATININE LEVEL versus CALCIFICATION 
Patients with serum creatinine level >5 mg/dL represented 40% of patients 
with calcification. Only 10% of patients with calcification had serum creatinine 
in the range below 2 mg/dL. Patients with higher levels of serum creatinine 
showed more incidence of calcification (p = 0.001) [Table 16, Figure 27]. 
Patients with serum creatinine level ≤2 mg/dL had a mean composite score of 
1.50 (SD = 0.707), whereas those with serum creatinine level >5 mg/dL a mean 
score of 11.13 (SD =2.696). Degree of calcification was also strongly associated 
with serum creatinine level (p <0.001) [Table 17, Figure 28]. 
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Table 16: Serum creatinine level versus calcification 
Creatinine 
[mg/dL] 
Calcification 
Total P value 
Present Absent 
≤2 
2 11 13 
0.001 
10.0% 27.5% 21.7% 
2-3 
1 10 11 
5.0% 25.0% 18.3% 
3-4 
5 3 8 
25.0% 7.5% 13.3% 
4-5 
4 14 18 
20.0% 35.0% 30.0% 
>5 
8 2 10 
40.0% 5.0% 16.7% 
Total 
20 40 60 
33.3% 66.7% 100% 
 
Table 17: Serum creatinine level versus degree of calcification 
Creatinine 
[mg/dL] 
n Mean 
Standard 
deviation 
P value 
≤2 2 1.50 0.707 
<0.001 
2-3 1 4.00 0.000 
3-4 5 4.60 1.140 
4-5 4 9.75 2.217 
>5 8 11.13 2.696 
Total 20 7.90 4.103 
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Figure 27: Serum creatinine level versus calcification 
 
 
Figure 28: Serum creatinine level versus degree of calcification 
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STAGE OF CKD versus CALCIFICATION 
Two out of 15 patients in stage 3 (13.3%), 6 out of 17 patients in stage 4 
(35.3%) and 12 out of 28 patients in stage 5 (42.9%) showed evidence of 
calcification. Among patients with calcification, 10% were in stage 3, 30% were 
in stage 4 and 60% were in stage 5 (n = 20). 
Even though it appears that progression of the disease is associated with 
increased incidence of calcification, no statistically significant correlation was 
noted between the stage of the disease and presence of calcification (p = 0.144) 
[Table 18, Figure 29]. 
Table 18: Stage of CKD versus calcification 
Stage 
Calcification 
Total P value 
Present Absent 
3 
2 13 15 
0.144 
10.0% 32.5% 25.0% 
4 
6 11 17 
30.0% 27.5% 28.3% 
5 
12 16 28 
60.0% 40.0% 46.7% 
Total 
20 40 60 
33.3% 66.7% 100% 
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Figure 29: Stage of CKD versus calcification 
 
 
 
Figure 30: Stage of CKD versus degree of calcification 
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Mean composite score was 1.50 (SD = 0.707) in stage 3, 4.50 (SD = 1.049) in 
stage 4 and 10.67 (SD = 2.535) in stage 5. While stage of CKD was not 
associated with incidence of calcification, it had a significant correlation with 
the severity of calcification (p <0.001) [Table 19, Figure 30]. 
Table 19: Stage of CKD versus degree of calcification 
Stage n Mean 
Standard 
deviation 
P value 
3 2 1.50 0.707 
<0.001 
4 6 4.50 1.049 
5 12 10.67 2.535 
Total 20 7.90 4.103 
 
DIABETES versus CALCIFICATION 
Table 20: Diabetes versus calcification 
Diabetes 
Calcification 
Total P value 
Present Absent 
Diabetics 
9 8 17 
0.043 
45.0% 20.0% 28.3% 
Non-diabetics 
11 32 43 
55.0% 80.0% 71.1% 
Total 
20 40 60 
33.3% 66.7% 100% 
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Figure 31: Diabetes versus calcification 
Out of 17 diabetic patients, 9 patients (52.9%) had calcification while 11 
patients (25.6%) among 43 non-diabetics showed evidence of calcification. 
Mean composite score was 8.56 (SD = 3.321) among diabetic patients and 7.36 
(SD = 4.739) among non-diabetic patients. Diabetes was associated with 
presence (p = 0.043) but not with degree (p = 0.533) of calcification [Table 20, 
Table 21, Figure 31, Figure 32]. 
Table 21: Diabetes versus degree of calcification 
Diabetes n Mean 
Standard 
deviation 
P value 
Diabetics 9 8.56 3.321 
0.533 
Non-diabetics 11 7.36 4.739 
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Figure 32: Diabetes versus degree of calcification 
HYPERTENSION versus CALCIFICATION 
Fourteen out of 31 hypertensives (45.2%) and 6 out of 29 non-hypertensives 
(20.7%) had calcification. 
Table 22: Hypertension versus calcification 
Hypertension 
Calcification 
Total P value 
Present Absent 
Hypertensives 
14 17 31 
0.044 
70.0% 42.5% 51.7% 
Non-hypertensives 
6 23 29 
30.0% 57.5% 48.3% 
Total 
20 40 60 
33.3% 66.7% 100% 
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Figure 33: Hypertension versus calcification 
Mean composite score was 8.50 (SD = 4.653) among hypertensives and 6.50 
(SD = 2.074) among non-hypertensives. 
Hypertension was associated with an increased incidence (p = 0.044) of 
calcification but not with the severity (p = 0.331) of calcification [Table 22, 
Table 23, Figure 33, Figure 34]. 
Table 23: Hypertension versus degree of calcification 
Hypertension n Mean 
Standard 
deviation 
P value 
Hypertensives 14 8.50 4.653 
0.331 
Non-hypertensives 6 6.50 2.074 
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Figure 34: Hypertension versus degree of calcification 
SMOKING versus CALCIFICATION 
38.1% of smokers (n = 21) and 30.8% of non-smokers (n = 39) 
demonstrated vascular calcification. 
Table 24: Smoking versus calcification 
Smoking 
Calcification 
Total P value 
Present Absent 
Smokers 
8 13 21 
0.566 
40.0% 32.5% 35.0% 
Non-smokers 
12 27 39 
60.0% 67.5% 65.0% 
Total 
20 40 60 
33.3% 66.7% 100% 
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Figure 35: Smoking versus calcification 
Mean composite score was 8.75 (SD = 4.713) among smokers and it was 
7.33 (SD = 3.750) among non-smokers. 
Smoking was neither associated with the presence (p = 0.566) nor the 
degree (p = 0.464) of vascular calcification [Table 24, Table 25, Figure 35, 
Figure 36]. 
Table 25: Smoking versus degree of calcification 
Smoking n Mean 
Standard 
deviation 
P value 
Smokers 8 8.75 4.713 
0.464 
Non-smokers 12 7.33 3.750 
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Figure 36: Smoking versus degree of calcification 
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DISCUSSION 
The role of vascular calcification in augmenting the cardiovascular risk in 
CKD patients has been well established. Current knowledge about the factors 
and mechanisms involved in the development of vascular calcification indicates 
that the biology of vascular calcification differs significantly between CKD 
patients who are on dialysis and pre-dialysis CKD patients. 
In our study, we analyzed the patient characteristics and biochemical 
parameters of 60 CKD patients who were in stages 3 to 5. Patients who were on 
any form of dialysis were excluded from the study. 
Univariate analysis was performed between abdominal aortic calcification 
score and the following factors: age, sex, duration of CKD, serum creatinine, 
stage of CKD, serum calcium, serum phosphorus, serum PTH, diabetes, 
hypertension and smoking. 
Age was not associated with presence or severity of calcification in our 
study. Calcification was noted in most of the age groups. No correlation was 
seen between sex and calcification also. Both males and females had similar 
prevalence of calcification. 
Duration of CKD has got a positive correlation with calcification but it did 
not influence on the severity of calcification. Serum creatinine level showed 
significant association both for the presence as well as degree of calcification. 
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Stage of CKD did not appear to predict the presence of calcification, 
whereas patients in advanced stage of CKD had more severe calcification than 
patients in early stage of the disease. 
Hypocalcemia is associated with more prevalence of calcification and degree 
of hypocalcemia was correlated with degree of calcification. Hence, treatment 
with vitamin D analogs seems reasonable to prevent hypocalcemia apart from 
controlling secondary hyperparathyroidism. 
Hyperphosphatemia is also an important risk factor for vascular 
calcification. It has also been proposed as one of the causative factors involved 
in vascular calcification. Most of the treatment options are targeted against 
hyperphosphatemia. Non-calcium containing phosphate binders are preferred 
in the management of hyperphosphatemia in the presence of vascular 
calcification. 
Serum PTH levels were not associated with vascular calcification probably 
because both high turnover states as well as low turnover states are associated 
with vascular calcification and we did not do bone biopsy to differentiate 
between these entitites. 
Both diabetes and hypertension were associated with presence of 
calcification but not with the degree of calcification. No association was noted 
between smoking and vascular calcification. 
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Comparison of pulse pressure between patients with calcification and 
without calcification revealed a statistically significant difference between the 
groups but the difference between the means was less. 
The results obtained in our study correlates with the study done by Hanada 
et al [22] using CT based imaging techniques. The prevalence of vascular 
calcification was more in their study because the use of CT scan improved the 
sensitivity. 
The CORD study group [32] applied the same technique of assessing 
abdominal aortic calcification in the hemodialysis population. 
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LIMITATIONS OF THE STUDY 
1. Abdominal aortic radiography does not differentiate between intimal 
calcification and medial calcification which is peculiar of CKD 
2. Association of degree of vascular calcification with cardiovascular 
outcome requires prospective long term follow up study design 
3. Most of the patients were diagnosed in the stage of established CKD and 
hence no association could be made between the etiology of the disease 
and vascular calcification 
4. Small size of the study population limits our ability to extrapolate the 
results to the community level 
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CONCLUSION 
Because of various factors like westernization, the incidence and prevalence 
of diabetes which is one the most common risk factor for the development of 
CKD is expected to rise in the near future. CKD significantly increases the 
burden on the health care expenditure. CKD is not just a disease of the kidneys 
as evidenced by its various manifestations and complications in almost any 
system of the body. Improvement in the outcome of patients with CKD 
requires addressing all the aspects of the disease. Mineral and Bone Disorders 
in CKD pose significant health problems. Vascular calcification is one of the 
important components of CKD-MBD and it is associated with increased 
cardio-vascular mortality and morbidity. Risk factors for the development of 
vascular calcification like hypocalcemia and hyperphosphatemia require proper 
therapy and monitoring to minimize vascular calcification which in turn could 
lead to better patient outcomes. 
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ASSESSMENT OF VASCULAR CALCIFICATION IN CHRONIC KIDNEY 
DISEASE PATIENTS 
Name : 
Age/Sex : Weight : 
IP No : Diagnosis : 
Patient ID No : Duration : 
Patient characteristics Medications 
❏ Smoking ❏ Calcium containing phosphate binders 
❏ Alcoholism ❏ Statins 
❏ Diabetes ❏ ACE inhibitors 
❏ Systemic hypertension ❏ Others  
 
Vascular complications 
❏ Coronary events ❏ Cerebrovascular events 
❏ Peripheral vascular diseases  
 
Clinical examination 
❏ Vessel wall thickening ❏ Skeletal abnormalities 
❏ Carotid bruit Upper limb BP   
❏ Renal bruit Lower limb BP   
 
INVESTIGATIONS 
RFT LFT 
Glucose (Fasting)  mg/dL Total bilirubin  mg/dL 
Urea  mg/dL Direct bilirubin  mg/dL 
Creatinine  mg/dL SGOT  U/L 
Electrolytes SGPT  U/L 
Na+  mEq/l ALP  U/L 
K+  mEq/l Total protein  g/dL 
Ca2+  mg/dL Albumin  g/dL 
PO42-  mg/dL eGFR  mL/min 
STAGE  
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Fasting lipid profile Others 
Total cholesterol  mg/dL Hemoglobin  g/dL 
LDL  mg/dL PTH  pg/mL 
HDL  mg/dL Chest X-ray  
Triglycerides  mg/dL USG KUB  
 
Lateral lumbar radiography 
Level 
Affected 
segment 
Anterior wall 
range 
Posterior 
wall range 
Anterior-posterior 
severity range 
L1     
L2     
L3     
L4     
Affected 
segments 
score 
 Composite score  
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16 63 M 61 4.5 N N Y Y 130 80 50 9.3 128 63 3.4 128 4.2 8.5 4.3 62 19.19 4 2 5 
17 63 F 61 3 N N Y N 130 80 50 7.9 136 82 4.7 131 4.1 8.4 4.3 213 11.8 5 0 0 
18 60 F 68 3 N N Y N 120 70 50 9.2 148 61 3.3 135 4.2 8.6 4.6 152 19.46 4 2 6 
19 62 F 68 1.5 N N N N 130 70 60 9.6 70 67 3 129 4.2 8.7 4.1 112 20.87 4 0 0 
20 61 F 68 3.5 N N N N 130 80 50 9.6 113 49 2.9 134 3.9 8.7 4.5 92 21.87 4 0 0 
21 67 M 63 3 N N N N 120 70 50 8.4 78 78 4.6 134 4.9 8.6 4.3 196 13.89 5 0 0 
22 62 M 60 5 N N N N 120 80 40 7.9 64 84 5.2 132 5 8.4 4.9 230 12.5 5 2 7 
23 54 M 64 4.5 Y Y N N 124 76 48 9.8 84 64 1.6 136 3.9 9.1 4 84 47.78 3 0 0 
24 69 M 56 5 Y Y Y Y 150 90 60 8.6 116 67 4.2 130 4.7 8.5 4.5 196 13.15 5 0 0 
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25 65 F 61 5.5 N N Y N 120 70 50 7.6 128 68 4.9 132 4.3 8.4 4.9 238 11.02 5 2 7 
26 52 M 69 9 N N N Y 130 90 40 10.4 92 49 1.8 137 3.8 9 3.7 89 46.85 3 1 1 
27 66 F 60 3.5 N N N N 124 80 44 8.4 66 76 4.5 136 4.3 8.6 4.3 190 11.65 5 0 0 
28 56 M 62 5 N N Y N 124 84 40 10.3 126 58 2.1 134 3.8 8.9 3.6 68 34.44 3 0 0 
29 65 M 58 6 Y N Y Y 140 70 70 7.8 146 76 5.1 129 4.8 8.5 4.9 276 11.85 5 2 8 
30 56 M 56 3.5 N N N Y 130 84 46 9.6 100 59 2.5 132 3.9 8.8 4.3 110 26.13 4 0 0 
31 53 M 66 4.5 Y N N N 110 80 30 9.8 98 43 2.2 128 3.8 9.1 4.1 38 36.25 3 0 0 
32 65 F 62 5 N N Y Y 136 90 46 7.3 110 84 5.1 134 4.7 8.3 5.3 84 10.76 5 3 13 
33 60 M 58 3.5 N N N N 130 80 50 8.4 75 68 4.8 132 4.8 8.6 4.6 168 13.43 5 0 0 
34 63 M 58 3 Y N N N 120 70 50 9.5 96 68 2.8 136 4.1 8.9 4.1 132 22.15 4 0 0 
35 64 M 59 5.5 Y N N N 120 70 50 9.1 84 67 3.1 134 4.1 8.9 3.9 158 20.09 4 2 5 
36 63 M 57 3.5 N N Y Y 140 90 50 7.8 112 67 4.9 129 4.9 8.4 5.1 246 12.44 5 3 12 
37 64 M 57 7 N N Y N 128 76 52 8.3 124 69 5.1 138 4.9 8.6 4.7 189 11.8 5 0 0 
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38 63 M 58 9 Y N N Y 136 70 66 8.2 68 68 4.9 130 4.2 8.5 4.8 84 12.66 5 3 11 
39 65 M 59 4.5 N Y N N 110 80 30 8.6 86 67 4.6 129 4.8 8.4 4.9 256 13.36 5 0 0 
40 64 F 62 4 N N N N 120 70 50 8.4 118 68 4.6 134 4.8 8.5 4.8 193 12.09 5 0 0 
41 57 M 62 3 Y Y N N 126 84 42 11.5 88 68 1.6 130 4.1 8.9 3.1 56 44.67 3 0 0 
42 60 M 54 3 Y Y N Y 130 70 60 8.1 72 84 5.3 134 4.3 8.4 5 278 11.32 5 3 15 
43 58 M 57 4 Y N N Y 136 86 50 8.3 86 67 4.8 129 4.6 8.5 4.7 231 13.52 5 0 0 
44 67 M 59 4.5 N N N Y 150 80 70 7.5 76 75 4.9 129 4.7 8.4 4.9 246 12.21 5 2 9 
45 65 M 58 6 N N N Y 120 80 40 8.9 104 50 3.4 132 4.7 8.6 3.9 156 17.77 4 1 3 
46 64 M 60 4 N N N Y 140 80 60 9.3 76 69 2.8 132 3.9 8.9 4.1 153 22.62 4 0 0 
47 64 M 58 2.5 Y Y Y Y 130 80 50 7.9 138 69 5.1 129 4.2 8.6 4.7 280 12 5 3 12 
48 65 F 63 2.5 N N N Y 120 76 44 9.1 101 58 2.8 135 3.8 8.8 3.9 86 19.92 4 0 0 
49 49 F 70 5.5 N N N N 120 70 50 10.6 68 58 1.4 134 3.7 8.9 3.8 98 53.72 3 0 0 
50 53 F 68 4 N N N Y 136 94 42 10.1 76 64 1.9 132 3.8 9.1 3.8 79 36.76 3 0 0 
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51 65 F 63 4.5 N N N N 120 80 40 8 92 67 4.6 129 3.8 8.7 4.5 184 12.13 5 0 0 
52 60 M 62 2.5 Y N N Y 140 70 70 9.3 85 64 3.2 129 4.2 9 4.2 84 21.53 4 0 0 
53 43 F 65 4.5 N N Y N 110 70 40 11.1 130 62 1.5 139 3.4 9.6 3.9 72 49.62 3 0 0 
54 64 M 58 2.5 Y N N Y 140 100 40 8.9 68 72 4.8 126 4.9 8.4 4.6 153 12.75 5 0 0 
55 48 F 67 2 N N N Y 130 80 50 10.5 98 68 1.8 128 3.5 9 3.7 59 40.43 3 0 0 
56 63 F 62 4 N N N Y 136 80 56 9.1 96 64 2.9 129 3.7 8.4 4.5 163 19.43 4 1 4 
57 54 M 68 5.5 Y N N Y 140 90 50 10.3 112 60 1.8 136 3.2 8.9 3.6 23 45.12 3 0 0 
58 62 M 56 4.5 Y Y Y N 110 60 50 8.9 136 64 3.2 132 4.6 8.8 4.2 148 18.96 4 2 4 
59 62 M 58 2 N N N N 124 86 38 8.3 84 78 4.8 129 4.5 8.6 4.5 198 13.09 5 0 0 
60 64 M 62 4 N N N N 110 80 30 9.6 84 61 2.8 134 4.2 8.8 4 124 23.37 4 0 0 
 
